Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Alterations in the balance of the gut microbota drive the persistent inflammation in Crohn’s disease. A diet containing high levels of prebiotic carbohydrate such as Fructooligosaccharides (FOS) Oligofructose / Oligofructan will increase colonic bifidobacteria and induce immunoregulatory dendritic and epithelial cell responses in patients with Crohn’s disease. This will result in resolution of intestinal inflammation and a reduction in disease activity.
Primary outcome measures:
The primary endpoint is clinical response to therapy at week four. Clinical response will be defined as a reduction in the Crohn’s disease activity index of at least 70 points from baseline.
The authors' conclusion was: An adequately powered placebo-controlled trial of FOS showed no clinical benefit in patients with active Crohn’s d…